Evidence map›Paper›PMID 23686308›Full record

ArticleOncogene2014

Targeting Gli transcription activation by small molecule suppresses tumor growth.

G Bosco-Clément, F Zhang, Z Chen, H-M Zhou, H Li, I Mikami, T Hirata, A Yagui-Beltran, N Lui, H T Do and 12 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 3 countries.

G Bosco-ClémentThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
F Zhang1] Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA [2] Tsinghua University Graduate School at Shenzhen, Division of Life and Health Sciences, Shenzhen, China.
Z Chen1] Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA [2] School of Life Sciences, Tsinghua University, Beijing, China.
H-M ZhouSchool of Life Sciences, Tsinghua University, Beijing, China.
H LiThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
I Mikami1] Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA [2] Department of Surgery, Division of Thoracic Surgery, Nippon Medical School, Tokyo, Japan.
T Hirata1] Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA [2] Department of Surgery, Division of Thoracic Surgery, Nippon Medical School, Tokyo, Japan.
A Yagui-BeltranThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
N LuiThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
H T DoThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
T ChengThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
H-H TsengThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
H ChoiThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
L-T FangThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
I-J KimThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
D Yue1] Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA [2] Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
C WangDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Q Zheng1] Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA [2] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Thoracic Surgery II, Peking University Cancer Hospital and Institute, Beijing, China.
N FujiiDepartment of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, TN, USA.
M MannDivision of Cardiothoracic Surgery, Department of Surgery, University of California, San Francisco, CA, USA.
D M JablonsThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
B HeThoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
University of California, San Francisco · USSt. Jude Children's Research Hospital · USTianjin Medical University Cancer Institute and Hospital · CNTsinghua University · CN

Funding

Inflammation and Lung CarcinogenesisR01CA132566 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COUSSENS, LISA M., JABLONS, DAVID M. · 2008 to 2012
$1.4M
Small molecule inhibitors of Wnt-2 transcription in NSCLCR01CA125030 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HE, BIAO · 2009 to 2011
$952k
NCI NIH HHS R01 CA125030NCI NIH HHS R01CA125030NCI NIH HHS R01 CA132566NCI NIH HHS R01CA132566
6 · The paper itself

Abstract

Targeted inhibition of Hedgehog signaling at the cell membrane has been associated with anticancer activity in preclinical and early clinical studies. Hedgehog signaling involves activation of Gli transcription factors that can also be induced by alternative pathways. In this study, we identified an interaction between Gli proteins and a transcription coactivator TBP-associated factor 9 (TAF9), and validated its functional relevance in regulating Gli transactivation. We also describe a novel, synthetic small molecule, FN1-8, that efficiently interferes with Gli/TAF9 interaction and downregulate Gli/TAF9-dependent transcriptional activity. More importantly, FN1-8 suppresses cancer cell proliferation in vitro and inhibits tumor growth in vivo. Our results suggest that blocking Gli transactivation, an important control point of multiple oncogenic pathways, may be an effective anticancer strategy.

Indexed as

AnimalsCell Line, TumorCell ProliferationFemaleHCT116 CellsHedgehog ProteinsHEK293 CellsHT29 CellsHumansImmunoblottingMiceMice, NudeNeoplasmsNIH 3T3 CellsOligonucleotide Array Sequence AnalysisProtein BindingFN1-8 compoundGLI1 protein, humanHedgehog ProteinsPyrazolesSmall Molecule LibrariesTAF9 protein, humanTATA-Binding Protein Associated FactorsTranscription FactorsTranscription Factor TFIIDZinc Finger Protein GLI1

Identifiers

PMID23686308
PMCPMC3947751
OpenAlexW2080823574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.